NewLimit

About NewLimit

NewLimit develops medicines that reprogram the epigenome to restore regenerative potential in aged and diseased cells, using functional genomics, pooled perturbation screening and machine learning at large scale.

NewLimit pairs ambitious longevity science with an unusually hands-on culture — there are no pure-manager roles, and everyone, including leaders, spends part of their time executing at the bench or in code. Scientists run perturbation experiments and machine-learning models at remarkable scale on a genuinely frontier problem, with competitive pay, equity and strong benefits.

• Frontier mission: epigenetic reprogramming to extend healthspan.
• Everyone executes — no pure-manager roles; deep ownership.
• Large-scale single-cell and ML work at unprecedented scale.
• $435M Series C (Jun 2026) funds a long, ambitious roadmap.

Benefits & perks

Funding & momentum

No recent funding round on record. We flag new raises as a hiring signal — check back or follow the GTM Talent Tracker →

Open roles